benserazide has been researched along with Movement Disorders in 37 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "Ten patients with a diagnosis of idiopathic Parkinson's disease and motor fluctuations otherwise unresponsive to conventional therapy were selected." | 2.67 | [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. ( Casas Parera, I; Diaz, S; Fernández Pardal, MM; Gatto, E; Micheli, F, 1991) |
| "Six patients with restless legs syndrome (RLS) and periodic movements during sleep (PMS) received placebo or L-dopa in a double-blind study." | 2.66 | Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. ( Brodeur, C; Godbout, R; Marinier, R; Montplaisir, J, 1988) |
| " During the first month the dosage titration was aimed at finding the optimal therapeutic effect." | 2.66 | Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy. ( Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987) |
| "In a open study in 13 patients with Parkinson's disease with 'on-off' fluctuations, all (n = 3) or part (n = 10) of the usual intake of levodopa (with peripheral decarboxylase inhibitor) was replaced by Madopar HBS for 5-122 days (median 35)." | 2.66 | Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. ( Marion, MH; Marsden, CD; Quinn, NP, 1987) |
| " At the beginning the patients were switched from standard Madopar to Madopar HBS, initially keeping constant L-dopa dosage and the number of daily doses." | 2.66 | Open clinical study of Madopar HBS. ( Ludin, HP, 1987) |
| " However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar." | 2.66 | Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study. ( D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP, 1987) |
| " For the first few days (up to 1 week) dosage and number of daily intakes of HBS were the same as those of the standard formulation." | 2.66 | Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations. ( Baas, H; Fischer, PA, 1987) |
| " The overall increase in dosage of levodopa with Madopar HBS was 54% in comparison with the initial standard Madopar dosage." | 2.66 | Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment. ( Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J, 1987) |
| "Pre-treatment with benserazide for up to 3h did not alter the motor response to L-DOPA compared to simultaneous administration with L-DOPA." | 1.36 | The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. ( Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G, 2010) |
| " In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS." | 1.27 | Madopar HBS in Parkinson patients with nocturnal akinesia. ( Jansen, EN; Meerwaldt, JD, 1988) |
| " At the end of the dosage adaptation phase (9 weeks) most patients improved; in patients with 'on-off' phenomenon, parkinsonism became less severe, on periods were longer, and fluctuations decrease; end-of-dose impairment resolved in 4 patients." | 1.27 | Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations. ( Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A, 1987) |
| " The dosage was adjusted until optimal response was obtained." | 1.27 | Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. ( Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO, 1987) |
| " In all patients of the first group, after 3 months on stable 'optimal' dosage schedule, the previous L-dopa treatment was abruptly replaced, dose for dose, from one day to another by Madopar HBS, a new controlled-release form of Madopar." | 1.27 | Therapeutic value of Madopar HBS: judgment after 2 years experience. ( Siegfried, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (70.27) | 18.7374 |
| 1990's | 8 (21.62) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (8.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knopp, C | 1 |
| Häusler, M | 1 |
| Müller, B | 1 |
| Damen, R | 1 |
| Stoppe, A | 1 |
| Mull, M | 1 |
| Elbracht, M | 1 |
| Kurth, I | 1 |
| Begemann, M | 1 |
| Tayarani-Binazir, KA | 1 |
| Jackson, MJ | 1 |
| Fisher, R | 1 |
| Zoubiane, G | 1 |
| Rose, S | 1 |
| Jenner, P | 1 |
| Dill, P | 1 |
| Wagner, M | 1 |
| Somerville, A | 1 |
| Thöny, B | 1 |
| Blau, N | 1 |
| Weber, P | 1 |
| Fernández Pardal, MM | 1 |
| Gatto, E | 1 |
| Micheli, F | 1 |
| Casas Parera, I | 1 |
| Diaz, S | 1 |
| Bächli, E | 1 |
| Albani, C | 2 |
| Atchison, PR | 1 |
| Thompson, PD | 1 |
| Frackowiak, RS | 1 |
| Marsden, CD | 2 |
| Buck, A | 1 |
| Imai, H | 1 |
| Nakamura, T | 1 |
| Kondo, T | 1 |
| Narabayashi, H | 1 |
| Harder, S | 1 |
| Baas, H | 2 |
| de Mello, MT | 1 |
| Poyares, DL | 1 |
| Tufik, S | 1 |
| Rinne, UK | 3 |
| Birket-Smith, E | 2 |
| Dupont, E | 2 |
| Hansen, E | 2 |
| Hyyppä, M | 1 |
| Marttila, R | 1 |
| Mikkelsen, B | 2 |
| Pakkenberg, H | 1 |
| Presthus, J | 1 |
| Siirtola, T | 1 |
| Sonninen, V | 1 |
| Barbeau, A | 2 |
| Roy, M | 1 |
| Korten, JJ | 1 |
| Keyser, A | 1 |
| Joosten, EM | 1 |
| Gabreëls, FJ | 1 |
| Pacchetti, C | 1 |
| Martignoni, E | 1 |
| Sibilla, L | 1 |
| Bruggi, P | 1 |
| Turla, M | 1 |
| Nappi, G | 1 |
| d'Anglejan Chatillon, J | 1 |
| Brodeur, C | 1 |
| Montplaisir, J | 1 |
| Godbout, R | 1 |
| Marinier, R | 1 |
| Csanda, E | 1 |
| Tárczy, M | 1 |
| Takáts, A | 1 |
| Rondot, P | 2 |
| Ziegler, M | 1 |
| Aymard, N | 1 |
| Holzer, J | 1 |
| Quinn, NP | 1 |
| Marion, MH | 1 |
| Ludin, HP | 1 |
| Nordera, GP | 1 |
| Lorizio, A | 1 |
| Lion, P | 1 |
| Durisotti, C | 1 |
| D'Andrea, G | 1 |
| Ferro-Milone, F | 1 |
| Fischer, PA | 1 |
| Poewe, WH | 1 |
| Lees, AJ | 2 |
| Stern, GM | 1 |
| Jansen, EN | 2 |
| Meerwaldt, JD | 2 |
| Heersema, T | 1 |
| van Manen, J | 1 |
| Speelman, JD | 1 |
| Chouza, C | 1 |
| Romero, S | 1 |
| de Medina, O | 1 |
| Aljanati, R | 1 |
| Scarmelli, A | 1 |
| Caamano, JL | 1 |
| Gonzales Panizza, V | 1 |
| Jensen, NO | 1 |
| Mikkelsen, BO | 1 |
| Siegfried, J | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Dumas, RJ | 1 |
| Birkmayer, W | 1 |
| Linauer, W | 1 |
| Mentasti, M | 1 |
| Riederer, P | 1 |
| Boudin, G | 1 |
| Pépin, B | 1 |
| Guillard, A | 1 |
| Fabiani, JM | 1 |
| Haguenau, M | 1 |
| Mars, H | 1 |
| Gillo-Joffroy, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait[NCT01071590] | 45 participants (Actual) | Observational | 2010-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benserazide and Movement Disorders
| Article | Year |
|---|---|
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gai | 1993 |
14 trials available for benserazide and Movement Disorders
| Article | Year |
|---|---|
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Topics: Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement D | 1991 |
Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions.
Topics: Adult; Benserazide; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Ma | 1999 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Tri | 1975 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydr | 1975 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; | 1990 |
Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Topics: Benserazide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle A | 1988 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; | 1987 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship | 1987 |
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
22 other studies available for benserazide and Movement Disorders
| Article | Year |
|---|---|
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Child; Consanguinity; Dopamine Agents; Dr | 2019 |
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; | 2010 |
Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Behavior; Benserazide; Consanguinity; Developmental Di | 2012 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodo | 1994 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Huma | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor | 1993 |
Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1998 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyin | 1978 |
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Mid | 1976 |
Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; | 1975 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa | 1989 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; | 1986 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines | 1988 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydra | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Res | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship | 1987 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
[Dopamine and abnormal movements].
Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro | 1972 |
[Indications and results of monoamine treatment in parkinsonian syndromes].
Topics: Aged; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; | 1972 |
Adverse clinical side effects of levodopa therapy.
Topics: Antiparkinson Agents; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Ede | 1971 |